VANCOUVER, BC –November 2, 2020 – Izotropic Corporation (“Izotropic” or the “Company”) (CSE: IZO) (OTC US: IZOZF) (FSE: 1R3) is pleased to announce that it has entered into the following consulting agreements to broaden its market presence and investor base and to provide investor relations services for its shareholders:
Doug McKay and Associates have been engaged for a period of 12 months for a fee of $108,000.00. 300,000 stock options have been granted at an exercise price of $1.32. The stock option is in effect for two (2) years and vests immediately.
Mr. Dan Sammartino has been engaged as a dedicated investor and shareholder communications specialist. The initial agreement term is for twelve (12) months with a monthly fee of $5,000.00 and is subject to renewal. 200,000 stock options have been granted at an exercise price of $1.32. The stock option is in effect for two (2) years and vests immediately.
The Company has also granted an additional 200,000 stock options to third party consultants at an exercise price of $1.32. The stock options are in effect for two (2) years and vest immediately.
For Investor relations inquiries, please contact Dan Sammartino at 1-778-962-0234.
ON BEHALF OF THE BOARD
Chief Executive Officer
Investor Relations: 1-778-962-0234
About Izotropic Corp.
Izotropic Corporation and its wholly owned U.S. operating subsidiary, Izotropic Imaging Corp. have been established to commercialize the next generation of breast imaging technology for early diagnosis of breast cancer. The Izotropic Breast CT Imaging System produces high resolution breast images in 3D. A single 10 second breast CT scan acquires approximately 500 images, without painful breast compression, providing radiologists with fully 3D viewing of the scanned breast. Mammography scanning requires compression of the breast between 2 imaging plates, resulting in 2D images.
The Company has the exclusive worldwide license from the University of California, Davis to commercialize the technology developed by principal founder and Company director Dr. John M. Boone and researchers at UC Davis. The license includes all intellectual property, trade secrets, patents and patent-pending applications that are the foundation of the Company’s breast CT imaging platform.
Approximately $20 million in research funding and over 15 years of research and development have been invested in developing this groundbreaking breast CT imaging technology. Research includes a current, ongoing $2.9M U.S. clinical trial at UC Davis Medical Center.
The Company founders believe that this technology will be a disruptive entry to the market, overcoming many of the challenges faced by existing breast imaging modalities.
Forward Looking Statements
This document may contain forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.